Chapter 36
Chronic Kidney Disease-Mineral and Bone Disorder
Suetonia C. Palmer,
Giovanni F.M. Strippoli,
Jonathan C. Craig,
Donald A. Molony,
Suetonia C. Palmer
Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand
Search for more papers by this authorGiovanni F.M. Strippoli
Department of Emergency and Organ Transplantation University of Bari, Bari, Italy
School of Public Health University of Sydney, Sydney, NSW, Australia
Search for more papers by this authorJonathan C. Craig
College of Medicine and Public Health Flinders University, Adelaide, Australia
Search for more papers by this authorDonald A. Molony
Division of Renal Diseases and Hypertension and Center for Clinical Research and Evidence-Based Medicine, University of Texas Houston Medical School, Houston, USA
Search for more papers by this authorSuetonia C. Palmer,
Giovanni F.M. Strippoli,
Jonathan C. Craig,
Donald A. Molony,
Suetonia C. Palmer
Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand
Search for more papers by this authorGiovanni F.M. Strippoli
Department of Emergency and Organ Transplantation University of Bari, Bari, Italy
School of Public Health University of Sydney, Sydney, NSW, Australia
Search for more papers by this authorJonathan C. Craig
College of Medicine and Public Health Flinders University, Adelaide, Australia
Search for more papers by this authorDonald A. Molony
Division of Renal Diseases and Hypertension and Center for Clinical Research and Evidence-Based Medicine, University of Texas Houston Medical School, Houston, USA
Search for more papers by this authorBook Editor(s):Jonathan C. Craig MBChB, DipCH, MMed(Clin Epi), PhD, FAHMS,
Donald A. Molony MD,
Giovanni F.M. Strippoli MD, PhD, MPH, MM (Epi),
Jonathan C. Craig MBChB, DipCH, MMed(Clin Epi), PhD, FAHMS
Matthew Flinders Distinguished Professor Vice President and Executive Dean
College of Medicine and Public Health, Flinders University, Adelaide, Australia
Search for more papers by this authorDonald A. Molony MD
Professor of Medicine Distinguished Teaching Professor of the University of Texas System
Division of Renal Diseases and Hypertension AND Center for Clinical Research and Evidence-based Medicine, McGovern Medical School University of Texas, Houston, TX, USA
Search for more papers by this authorGiovanni F.M. Strippoli MD, PhD, MPH, MM (Epi)
Professor of Nephrology Adjunct Professor of Epidemiology
Department of Emergency and Organ Transplantation – University of Bari, Bari, Italy
School of Public Health, University of Sydney, Sydney, NSW, Australia
Search for more papers by this authorFirst published: 18 November 2022
Summary
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is commonly encountered in the later stages of chronic kidney failure (CKD). A range of treatments are used to correct the metabolic abnormalities observed with CKD-MBD. This chapter examines the evidence for management of CKD-MBD in adults, including transplant-related bone disease. The heterogeneity in clinical and biochemical abnormalities of CKD-MBD makes it difficult to determine its exact prevalence in patients with CKD. Diagnostic tests for renal osteodystrophy would ideally examine the essential properties of bone: strength for load bearing, flexibility to absorb energy, compression, and tension without fracture, and volume and weight to facilitate mobility. Phosphate binders reduce phosphorus absorption from dietary content through binding within the gut. Bisphosphonates are used widely for the treatment and prevention of osteoporosis and its complications in the general population.
References
- Palmer , S. , McGregor , D. , Craig , J. et al. ( 2009 ). Vitamin D compounds for people with chronic kidney disease not requiring dialysis . Cochrane Database Syst. Rev. ( 4 ) (Art. No.: CD008175). DOI: https://doi.org/10.1002/14651858.CD008175 .
- Palmer , S. , McGregor , D. , Craig , J. et al. ( 2009 ). Vitamin D compounds for people with chronic kidney disease requiring dialysis . Cochrane Database Syst. Rev. ( 4 ) (Art. No.: CD005633). DOI: https://doi.org/10.1002/14651858.CD005633.pub2 .
- Ballinger , A. , Palmer , S. , Nistor , I. et al. ( 2014 ). Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients . Cochrane Database Syst. Rev. ( 12 ) (Art. No.: CD006254). DOI: https://doi.org/10.1002/14651858.CD006254.pub2 .
- Navaneethan , S. , Palmer , S. , Vecchio , M. et al. ( 2011 ). Phosphate binders for preventing and treating bone disease in chronic kidney disease patients . Cochrane Database Syst. Rev. ( 2 ) (Art. No.: CD006023). DOI: https://doi.org/10.1002/14651858.CD006023.pub2 .
- Palmer , S. , Gardner , S. , Tonelli , M. et al. ( 2016 ). Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials . Am. J. Kidney Dis. 68 ( 5 ): 691 – 702 .
- Liu , Z. , Su , G. , Guo , X. et al. ( 2015 ). Dietary interventions for mineral and bone disorder in people with chronic kidney disease . Cochrane Database Syst. Rev. ( 9 ) (Art. No.: CD010350). DOI: https://doi.org/10.1002/14651858.CD010350.pub2 .
- Palmer , S. , Hayen , A. , Mackaskill , P. et al. ( 2011 ). Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis . JAMA 305 ( 11 ): 1119 – 1127 .
- Palmer , S. , McGregor , D.O. , and Strippoli , G.F. ( 2005 ). Interventions for preventing bone disease in kidney transplant recipients . Cochrane Database Syst. Rev. ( 2 ) (Art. No.:Cd005015).
- Hultcrantz , M. , Rind , D. , Akl , E.A. et al. ( 2017 ). The GRADE Working Group clarifies the construct of certainty of evidence . J. Clin. Epidemiol. 87 : 4 – 13 .
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group ( 2017 ). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) . Kidney Int. Supp. 7 : 1 – 59 .
- Moe , S. , Drüeke , T. , Cunningham , J. et al. ( 2006 ). Definition, evaluation, and classification of renal osteodystropy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) . Kidney Int. 69 ( 11 ): 1945 – 1953 .
- Levin , A. , Bakris , G. , Molitch , M. et al. ( 2007 ). Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease . Kidney Int. 71 : 31 – 38 .
- Bover , J. and Cozzolino , M. ( 2011 ). Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation . Kidney Int. Supp. 1 ( 4 ): 122 – 129 .
- Budoff , M. , Rader , D. , Reilly , M. et al. ( 2011 ). Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study . Am. J. Kidney Dis. 58 : 519 – 526 .
- Goodman , W. , Goldin , J. , Kuizon , B. et al. ( 2000 ). Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis . N. Engl. J. Med. 342 ( 20 ): 1478 – 1483 .
- Toussaint , N. , Lau , K. , Strauss , B. et al. ( 2008 ). Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease . Nephrol. Dial. Transplant. 23 ( 2 ): 586 – 593 .
- Julian , B. , Laskow , D. , Dubovsky , J. et al. ( 1991 ). Rapid loss of vertebral mineral density after renal transplantation . N. Engl. J. Med. 325 : 544 – 550 .
- Malluche , H. , Monier-Faugere , M.-C. , and Herberth , J. ( 2010 ). Bone disease after renal transplantation . Nat. Rev. Nephrol. 6 : 32 – 40 .
- Brandenburg , V. , Politt , D. , Ketteler , M. et al. ( 2004 ). Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation . Transplantation 77 : 1566 – 1571 .
- Lou , I. , Foley , D. , Odorico , S.K. et al. ( 2015 ). How well does renal transplantation cure hyperparathyroidism? Ann. Surg. 262 ( 4 ): 653 – 659 .
- Neves , C.L. , dos Reis , L.M. , Batista , D.G. et al. ( 2013 ). Persistence of bone and mineral disorders 2 years after successful kidney transplantation . Transplantation 96 ( 3 ): 290 – 296 .
- Cundy , T. , Hand , D. , Oliver , D. et al. ( 1985 ). Who gets renal bone disease before beginning dialysis? Br. Med. J. 290 : 271 – 275 .
- Ghazali , A. , Fardellone , P. , Pruna , A. et al. ( 1999 ). Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int. 55 ( 6 ): 2169 – 2177 .
- Clair , F. , Leenhardt , L. , Bourdeau , A. et al. ( 1987 ). Effect of calcitriol in the control of plasma calcium after parathyroidectomy. A placebo-controlled, double-blind study in chronic hemodialysis patients . Nephron 46 ( 1 ): 18 – 22 .
- Andress , D.L. , Norris , K.C. , Coburn , J.W. et al. ( 1989 ). Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure . N. Engl. J. Med. 321 ( 5 ): 274 – 279 .
- Hamdy , N.A. , Kanis , J.A. , Beneton , M.N. et al. ( 1995 ). Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure . BMJ 310 ( 6976 ): 358 – 363 .
- Larsson , T. , Nisbeth , U. , Ljunggren , O. et al. ( 2003 ). Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers . Kidney Int. 64 ( 6 ): 2272 – 2279 .
- Ben-Dov , I.Z. , Galitzer , H. , Lavi-Moshayoff , V. et al. ( 2007 ). The parathyroid is a target organ for FGF23 in rats . J. Clin. Invest. 117 ( 12 ): 4003 – 4008 .
- Hu , M.C. , Shi , M. , Zhang , J. et al. ( 2010 ). Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule . FASEB J. 24 ( 9 ): 3438 – 3450 .
- Gutierrez , O. , Isakova , T. , Rhee , E. et al. ( 2005 ). Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease . J. Am. Soc. Nephrol. 16 ( 7 ): 2205 .
- Hruska , K. , Mathew , S. , Memon , I. , and Saab , G. ( 2009 ). The pathogenesis of vascular calcification in the Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) . Semin. Nephrol. 29 ( 2 ): 156 – 165 .
- Moe , S. and Chen , N. ( 2008 ). Mechanisms of vascular calcification in chronic kidney disease . J. Am. Soc. Nephrol. 19 ( 2 ): 213 – 216 .
- Bouquegneau , A. , Salam , S. , Delanaye , P. et al. ( 2016 ). Bone disease after kidney transplantation . Clin. J. Am. Soc. Nephrol. 11 ( 7 ): 1282 – 1296 .
- Holick , M. , Binkley , N. , Bischoff-Ferrari , H. et al. ( 2011 ). Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline . J. Clin. Endocrinol. Metab. 96 ( 7 ): 1911 – 1930 .
- Sardiwal , S. , Magnusson , P. , Goldsmith , D. , and Lamb , E. ( 2013 ). Bone alkaline phosphatase in CKD-mineral and bone disorder . Am. J. Kidney Dis. 62 ( 4 ): 810 – 822 .
- Ureña , P. , Hruby , M. , Ferreira , A. et al. ( 1996 ). Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients . J. Am. Soc. Nephrol. 7 ( 3 ): 506 – 512 .
- Iimori , S. , Mori , Y. , Akita , W. et al. ( 2012 ). Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study . Nephrol. Dial. Transplant. 27 ( 1 ): 345 – 351 .
- Yenchek , R.H. , Ix , J.H. , Shlipak , M.G. et al. ( 2012 ). Bone mineral density and fracture risk in older individuals with CKD . Clin. J. Am. Soc. Nephrol. 7 ( 7 ): 1130 – 1136 .
- Sprague , S.M. , Bellorin-Font , E. , Jorgetti , V. et al. ( 2016 ). Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis . Am. J. Kidney Dis. 67 ( 4 ): 559 – 566 .
- Seeman , E. and Delmas , P. ( 2006 ). Bone quality -- the material and structural basis of bone strength and fragility . N. Engl. J. Med. 354 ( 21 ): 2250 – 2261 .
- U. S. Preventive Services Task Force ( 2011 ). Screening for osteoporosis: U. S. preventive services task force recommendation statement . Ann. Intern. Med. 154 ( 5 ): 356 – 364 .
- Ureña , P. , Bernard-Poenaru , O. , Ostertag , A. et al. ( 2003 ). Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients . Nephrol. Dial. Transplant. 18 ( 11 ): 2325 – 2331 .
- West , S.L. , Lok , C.E. , Langsetmo , L. et al. ( 2015 ). Bone mineral density predicts fractures in chronic kidney disease . J. Bone Miner. Res. 30 ( 5 ): 913 – 919 .
- Carvalho , A.B. , Carneiro , R. , Leme , G.M. et al. ( 2013 ). Vertebral bone density by quantitative computed tomography mirrors bone structure histomorphometric parameters in hemodialysis patients . J. Bone Miner. Metab. 31 ( 5 ): 551 – 555 .
- Nickolas , T.L. , Stein , E. , Cohen , A. et al. ( 2010 ). Bone mass and microarchitecture in CKD patients with fracture . J. Am. Soc. Nephrol. 21 ( 8 ): 1371 – 1380 .
- Moorthi , R. and Moe , S. ( 2013 ). Recent advances in the non-invasive diagnosis of renal osteodystrophy . Kidney Int. 84 ( 5 ): 886 – 894 .
- Leslie , W. , Lix , L. , Langsetmo , L. et al. ( 2011 ). Construction of a FRAX® model for the assessment of farcture probability in Canada and implications for treatment . Osteoporos Int. 22 ( 3 ): 817 – 827 .
- Naylor , K.L. , Garg , A.X. , Zou , G. et al. ( 2015 ). Comparison of fracture risk prediction among individuals with reduced and normal kidney function . Clin. J. Am. Soc. Nephrol. 10 ( 4 ): 646 – 653 .
- Naylor , K.L. , Leslie , W.D. , Hodsman , A.B. et al. ( 2014 ). FRAX predicts fracture risk in kidney transplant recipients . Transplantation 97 ( 9 ): 940 – 945 .
- Kauppila , L.I. , Polak , J.F. , Cupples , L.A. et al. ( 1997 ). New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study . Atherosclerosis 132 ( 2 ): 245 – 250 .
- Kraus , M. , Kalra , P. , Hunter , J. et al. ( 2015 ). The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study . Ther. Adv. Chronic Dis. 6 ( 3 ): 84 – 96 .
- de Bie , M. , Buiten , M. , Rotmans , J. et al. ( 2017 ). Abdominal aortic calcification on a plain X-ray and the relation with significant coronary artery disease in asymptomatic chronic dialysis patients . BMC Nephrol. 18 : 82 .
- Agatston , A.S. , Janowitz , W.R. , Hildner , F.J. et al. ( 1990 ). Quantification of coronary artery calcium using ultrafast computed tomography . J. Am. Coll. Cardiol. 15 ( 4 ): 827 – 832 .
- Rumberger , J.A. ( 2008 ). Coronary artery calcium scanning using computed tomography: clinical recommendations for cardiac risk assessment and treatment . Semin. Ultrasound CT MR. 29 ( 3 ): 223 – 229 .
- Braun , J. , Oldendorf , M. , Moshage , W. et al. ( 1996 ). Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients . Am. J. Kidney Dis. 27 ( 3 ): 394 – 401 .
- Park , M.Y. , Choi , S.J. , Kim , J.K. et al. ( 2011 ). Use of multidetector computed tomography for evaluating coronary artery disease in patients undergoing dialysis . Nephrology (Carlton) 16 ( 3 ): 285 – 289 .
- Lentine , K.L. , Costa , S.P. , Weir , M.R. et al. ( 2012 ). Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation . Circulation 126 ( 5 ): 617 – 663 .
- Alem , A.M. , Sherrard , D.J. , Gillen , D.L. et al. ( 2000 ). Increased risk of hip fracture among patients with end-stage renal disease . Kidney Int. 58 ( 1 ): 396 – 399 .
- Jadoul , M. , Albert , J.M. , Akiba , T. et al. ( 2006 ). Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study . Kidney Int. 70 ( 7 ): 1358 – 1366 .
- Coco , M. and Rush , H. ( 2000 ). Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone . Am. J. Kidney Dis. 36 ( 6 ): 1115 – 1121 .
- Elliott , M.J. , James , M.T. , Quinn , R.R. et al. ( 2013 ). Estimated GFR and fracture risk: a population-based study . Clin. J. Am. Soc. Nephrol. 8 ( 8 ): 1367 – 1376 .
- Ensrud , K.E. , Parimi , N. , Fink , H.A. et al. ( 2014 ). Estimated GFR and risk of hip fracture in older men: comparison of associations using cystatin C and creatinine . Am. J. Kidney Dis. 63 ( 1 ): 31 – 39 .
- Naylor , K.L. , Li , A.H. , Lam , N.N. et al. ( 2013 ). Fracture risk in kidney transplant recipients: a systematic review . Transplantation 95 ( 12 ): 1461 – 1470 .
- Naylor , K.L. , Jamal , S.A. , Zou , G. et al. ( 2016 ). Fracture incidence in adult kidney transplant recipients . Transplantation 100 ( 1 ): 167 – 175 .
- Senanayake , S. , Gunawardena , N. , Palihawadana , P. et al. ( 2017 ). Symptom burden in chronic kidney disease; a population based cross sectional study . BMC Nephrol. 18 ( 1 ): 228 .
- Murtagh , F.E. , Addington-Hall , J.M. , Edmonds , P.M. et al. ( 2007 ). Symptoms in advanced renal disease: a cross-sectional survey of symptom prevalence in stage 5 chronic kidney disease managed without dialysis . J. Palliat. Med. 10 ( 6 ): 1266 – 1276 .
- Murtagh , F.E. , Addington-Hall , J. , and Higginson , I.J. ( 2007 ). The prevalence of symptoms in end-stage renal disease: a systematic review . Adv. Chronic Kidney Dis. 14 ( 1 ): 82 – 99 .
- Block , G. , Hulbert-Shearon , T. , Levin , N. , and Port , F. ( 1998 ). Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study . Am. J. Kidney Dis. 31 ( 4 ): 607 – 617 .
- Block , G. , Klassen , P. , Lazarus , J. et al. ( 2004 ). Mineral metabolism, mortality, and morbidity in maintenance hemodialysis . J. Am. Soc. Nephrol. 15 ( 8 ): 2208 – 2218 .
- Wang , M. , Obi , Y. , Streja , E. et al. ( 2017 ). Association of parameters of mineral bone disorder with mortality in patients on hemodialysis according to level of residual kidney function . Clin. J. Am. Soc. Nephrol. 12 ( 7 ): 1118 – 1127 .
- National Kidney Foundation ( 2003 ). K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease . Am. J. Kidney Dis. 42 ( 4 Suppl 3 ): S1 – S201 .
- Alfrey , A. ( 1993 ). Aluminum toxicity in patients with chronic renal failure . Ther. Drug Monit. 15 : 593 – 597 .
- de Wolff , F. ( 1985 ). Toxicological aspects of aluminum poisoning in clinical nephrology . Clin. Nephrol. 24 ( Suppl 1 ): S9 – S14 .
- Canata-Andía , J. and Fernández-Martín , J. ( 2002 ). The clinical impact of aluminum overload in renal failure . Nephrol. Dial. Transplant. 17 ( Suppl 2 ): 17 – 20 .
- Andreoli , S. , Bergstein , J. , and Sherrard , D. ( 1984 ). Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis . N. Engl. J. Med. 310 : 1079 – 1084 .
-
Parkinson , I.
,
Ward , M.
,
Feest , T.
et al. (
1979
).
Fracturing dialysis osteodystrophy and dialysis encephalopathy. An epidemiological survey
.
Lancet
i
(
8113
):
406
–
409
.
10.1016/S0140-6736(79)90883-3 Google Scholar
- Berlyne , G.M. , Ben-Ari , J. , Pest , D. et al. ( 1970 ). Hyperaluminaemia from aluminum resins in renal failure . Lancet 2 ( 7671 ): 494 – 496 .
- Wrong , O.M. and Swales , J.D. ( 1970 ). Hyperaluminaemia form aluminium resins . Lancet 2 ( 7683 ): 1130 – 1131 .
- Salusky , I.B. , Foley , J. , Nelson , P. , and Goodman , W.G. ( 1991 ). Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease . N. Engl. J. Med. 324 ( 8 ): 527 – 531 .
- Tonelli , M. , Pannu , N. , and Manns , B. ( 2010 ). Oral phosphate binders in patients with kidney failure . N. Engl. J. Med. 362 ( 14 ): 1312 – 1324 .
- Chiu , Y.W. , Teitelbaum , I. , Misra , M. et al. ( 2009 ). Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients . Clin. J. Am. Soc. Nephrol. 4 ( 6 ): 1089 – 1096 .
- Spiegel , D.M. , Farmer , B. , Smits , G. , and Chonchol , M. ( 2007 ). Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study . J. Ren. Nutr. 17 ( 6 ): 416 – 422 .
- Block , G. , Wheeler , D. , Persky , M. et al. ( 2012 ). Effects of phosphate binders in moderate CKD . J. Am. Soc. Nephrol. 23 : 1407 – 1415 .
- Liu , Z. , Su , G. , Gui , X. et al. ( 2015 ). Dietary interventions for mineral and bone disorder in people with chronic kidney disease . Cochrane Database Syst. Rev. ( 9 ) (Art. No.: CD010350). DOI: https://doi.org/10.1002/14651858.CD010350.pub2 .
- Houston , J. , Smith , K. , Isakova , T. et al. ( 2013 ). Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease . J. Ren. Nutr. 23 ( 1 ): 12 – 20 .
- Selamet , U. , Tighiouart , H. , Sarnak , M.J. et al. ( 2016 ). Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3-5: The Modification of Diet in Renal Disease Study . Kidney Int. 89 ( 1 ): 176 – 184 .
- The FHN Trial Group ( 2010 ). In-center hemodialysis six times per week versus three times per week . N. Engl. J. Med. 363 : 2287 – 2300 .
- Rocco , M.V. , Lockridge , R.S. Jr. , Beck , G.J. et al. ( 2011 ). The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial . Kidney Int. 80 ( 10 ): 1080 – 1091 .
- Berl , T. , Berns , A.S. , Hufer , W.E. et al. ( 1978 ). 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study . Ann. Intern. Med. 88 ( 6 ): 774 – 780 .
- Bordier , P. , Zingraff , J. , Gueris , J. et al. ( 1978 ). The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy . Am. J. Med. 64 ( 1 ): 101 – 107 .
- DeLuca , H.F. and Avioli , L.V. ( 1970 ). Treatment of renal osteodystrophy with 25-hydroxycholecalciferol . Arch. Intern. Med. 126 ( 5 ): 896 – 899 .
- Brickman , A.S. , Coburn , J.W. , and Norman , A.W. ( 1972 ). Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D, in uremic man . N. Engl. J. Med. 287 ( 18 ): 891 – 895 .
- Brickman , A.S. , Coburn , J.W. , Massry , S.G. , and Norman , A.W. ( 1974 ). 1,25 Dihydroxy-vitamin D3 in normal man and patients with renal failure . Ann. Intern. Med. 80 ( 2 ): 161 – 168 .
- Christiansen , C. , Rodbro , P. , Christensen , M.S. , and Hartnack , B. ( 1981 ). Is 1,25-dihydroxy-cholecalciferol harmful to renal function in patients with chronic renal failure? Clin. Endocrinol. (Oxf). 15 ( 3 ): 229 – 236 .
- Christiansen , C. , Roodbro , P. , Christensen , M.S. et al. ( 1980 ). Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure . Contrib. Nephrol. 18 : 139 – 146 .
- Ritz , E. , Kuster , S. , Schmidt-Gayk , H. et al. ( 1995 ). Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial) . Nephrol. Dial. Transplant. 10 ( 12 ): 2228 – 2234 .
- Sprague , S.M. and Moe , S.M. ( 1992 ). Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol . Am. J. Kidney Dis. 19 ( 6 ): 532 – 539 .
- Dobrez , D.G. , Mathes , A. , Amdahl , M. et al. ( 2004 ). Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings . Nephrol. Dial. Transplant. 19 ( 5 ): 1174 – 1181 .
- Kovesdy , C.P. , Ahmadzadeh , S. , Anderson , J.E. , and Kalantar-Zadeh , K. ( 2008 ). Association of activated vitamin D treatment and mortality in chronic kidney disease . Arch. Intern. Med. 168 ( 4 ): 397 – 403 .
- Zheng , Z. , Shi , H. , Jia , J. et al. ( 2013 ). Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies . BMC Nephrol. 14 : 199 .
- Tentori , F. , Albert , J.M. , Young , E.W. et al. ( 2009 ). The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study . Nephrol. Dial. Transplant. 24 ( 3 ): 963 – 972 .
- Wang , A.Y. , Fang , F. , Chan , J. et al. ( 2014 ). Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial . J. Am. Soc. Nephrol. 25 ( 1 ): 175 – 186 .
- Thadhani , R. , Appelbaum , E. , Pritchett , Y. et al. ( 2012 ). Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial . JAMA 307 ( 7 ): 674 – 684 .
- Palmer , S.C. , McGregor , D.O. , Macaskill , P. et al. ( 2007 ). Meta-analysis: vitamin D compounds in chronic kidney disease . Ann. Intern. Med. 147 ( 12 ): 840 – 853 .
- Kandula , P. , Dobre , M. , Schold , J.D. et al. ( 2011 ). Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials . Clin. J. Am. Soc. Nephrol. 6 ( 1 ): 50 – 62 .
- Sprague , S.M. , Crawford , P.W. , Melnick , J.Z. et al. ( 2016 ). Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease . Am. J. Nephrol. 44 ( 4 ): 316 – 325 .
- Sprague , S.M. , Silva , A.L. , Al-Saghir , F. et al. ( 2014 ). Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease . Am. J. Nephrol. 40 ( 6 ): 535 – 545 .
- European Medicines Agency ( 2017 ). EPAR summary for the public . Mimpara. Cincalcet. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000570/human_med_000903.jsp&mid=WC0b01ac058001d124 (access 22 May 2021).
- Lindberg , J.S. , Culleton , B. , Wong , G. et al. ( 2005 ). Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study . J. Am. Soc. Nephrol. 16 ( 3 ): 800 – 807 .
- Charytan , C. , Coburn , J.W. , Chonchol , M. et al. ( 2005 ). Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis . Am. J. Kidney Dis. 46 ( 1 ): 58 – 67 .
- Strippoli , G.F. , Tong , A. , Palmer , S.C. et al. ( 2006 ). Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients . Cochrane Database Syst. Rev. ( 4 ) (Art. No.:Cd006254).
- Palmer , S.C. , Nistor , I. , Craig , J.C. et al. ( 2013 ). Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials . PLoS Med. 10 ( 4 ): e1001436 .
- Chertow , G.M. , Block , G.A. , Correa-Rotter , R. et al. ( 2012 ). Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis . N. Engl. J. Med. 367 ( 26 ): 2482 – 2244 .
- Parfrey , P.S. , Drueke , T. , Block , G.A. et al. ( 2015 ). The effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial . Clin. J. Am. Soc. Nephrol. 10 ( 5 ): 791 – 799 .
- Bell , G. , Huang , S. , Martin , K.J. , and Block , G.A. ( 2015 ). A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients . Curr. Med. Res. Opin. 31 ( 5 ): 943 – 952 .
- Block , G.A. , Bushinsky , D.A. , Cunningham , J. et al. ( 2017 ). Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials . JAMA 317 ( 2 ): 146 – 155 .
- Block , G.A. , Bushinsky , D.A. , Cheng , S. et al. ( 2017 ). Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial . JAMA 317 ( 2 ): 156 – 164 .
- Behets , G.J. , Spasovski , G. , Sterling , L.R. et al. ( 2015 ). Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism . Kidney Int. 87 ( 4 ): 846 – 856 .
- Lien , Y. , Silva , A. , and Whittman , D. ( 2005 ). Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism . Nephrol. Dial. Transplant. 20 ( 6 ): 1232 – 1237 .
- Palazzo , F. and Sadler , G. ( 2004 ). Minimally invasive parathyroidectomy . Br. Med. J. 328 ( 7444 ): 849 – 850 .
- Sejean , K. , Calmus , S. , Durand-Zaleski , I. et al. ( 2005 ). Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: a decision analysis . Eur. J. Endocrinol. 153 ( 6 ): 915 – 927 .
- Coen , G. , Calabria , S. , Bellinghieri , G. et al. ( 2001 ). Parathyroidectomy in chronic renal failure: short- and long-term results on parathyroid function, blood pressure and anemia . Nephron 88 ( 2 ): 149 – 155 .
- Gagne , E.R. , Urena , P. , Leite-Silva , S. et al. ( 1992 ). Short- and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients . J. Am. Soc. Nephrol. 3 ( 4 ): 1008 – 1017 .
- Lorenz , K. , Ukkat , J. , Sekulla , C. et al. ( 2006 ). Total parathyroidectomy without autotransplantation for renal hyperparathyroidism: experience with a qPTH-controlled protocol . World J. Surg. 30 ( 5 ): 743 – 751 .
- Young EW , Albert JM , Satayathum S , Goodkin DA , Pisoni RL , Akiba T , Akizawa T , Kurokawa K , Bommer J , Piera L , Port FK . Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study . Kidney International 2005 ; 67 ( 3 ): 1179 – 1187 .
- Brunelli , S.M. , Sibbel , S. , Do , T.P. et al. ( 2015 ). Facility dialysate calcium practices and clinical outcomes among patients receiving hemodialysis: a retrospective observational study . Am. J. Kidney Dis. 66 ( 4 ): 655 – 665 .
- Kim , H.W. , Kim , S.H. , Kim , Y.O. et al. ( 2015 ). Impact of dialysate calcium concentration on clinical outcomes in incident hemodialysis patients . Medicine (Baltimore) 94 ( 40 ): e1694 .
- Masterson , R. , Blair , S. , Polkinghorne , K.R. et al. ( 2017 ). Low versus high dialysate calcium concentration in alternate night nocturnal hemodialysis: a randomized controlled trial . Hemodial. Int. 21 ( 1 ): 19 – 28 .
- Ok , E. , Asci , G. , Bayraktaroglu , S. et al. ( 2016 ). Reduction of dialysate calcium level reduces progression of coronary artery calcification and improves low bone turnover in patients on hemodialysis . J. Am. Soc. Nephrol. 27 ( 8 ): 2475 – 2486 .
- Tentori , F. , McCullough , K. , Kilpatrick , R.D. et al. ( 2014 ). High rates of death and hospitalization follow bone fracture among hemodialysis patients . Kidney Int. 85 ( 1 ): 166 – 173 .
- Klawansky , S. , Komaroff , E. , Cavanaugh , P. Jr. et al. ( 2003 ). Relationship between age, renal function and bone mineral desnity in the US population . Osteoporos. Int. 14 : 570 – 576 .
- Cunningham , J. , Sprague , S. , Canata-Andía , J. et al. ( 2004 ). Osteoporosis in chronic kidney disease . Am. J. Kidney Dis. 43 ( 3 ): 566 – 571 .
- Domrongkitchaiporn , S. , Pongsakul , C. , Stitchantrakul , W. et al. ( 2001 ). Bone mineral density and histology in distal renal tubular acidosis . Kidney Int. 59 : 1086 – 1093 .
- Rodan , G. and Fleisch , H. ( 1986 ). Bisphosphonates: mechanism of action . J. Clin. Invest. 97 ( 12 ): 2692 – 2696 .
- Saha , H. , Castren-Kortekangas , P. , Ojanen , S. et al. ( 1994 ). Pharmacokinetics of clodronate in renal failure . J. Bone Miner. Metab. 9 ( 12 ): 1953 – 1958 .
- MacLean , C. , Newberry , S. , Maglione , M. et al. ( 2008 ). Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis . Ann. Intern. Med. 148 ( 3 ): 197 – 213 .
- Wilson , L.M. , Rebholz , C.M. , Jirru , E. et al. ( 2017 ). Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systematic review and meta-analysis . Ann. Intern. Med. 166 ( 9 ): 649 – 658 .
- Jamal , S.A. , Bauer , D.C. , Ensrud , K. et al. ( 2007 ). Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial . J. Bone Miner. Res. 22 ( 4 ): 503 – 508 .
- Miller , P. , Roux , C. , Boonen , S. et al. ( 2005 ). Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials . J. Bone Miner. Res. 20 : 2105 – 2115 .
- Aryoshi , T. , Eishi , K. , Sakamoto , I. et al. ( 2006 ). Effect of etirdronic acid on arterial calcification in dialysis patients . Clin. Drug Invest. 26 : 215 – 222 .
- Toussaint , N.D. , Lau , K.K. , Strauss , B.J. et al. ( 2010 ). Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial . Am. J. Kidney Dis. 56 ( 1 ): 57 – 68 .
- Markowitz , G. , Appel , G. , Fine , P. et al. ( 2001 ). Collapsing focal and segmental glomerulosclerosis following treatment with high-dose pamidronate . J. Am. Soc. Nephrol. 12 ( 6 ): 1164 – 1172 .
- Perazella , M.A. and Markowitz , G.S. ( 2008 ). Bisphosphonate nephrotoxicity . Kidney Int. 74 ( 11 ): 1385 – 1393 .
- McClung , M.R. , Lewiecki , E.M. , Cohen , S.B. et al. ( 2006 ). Denosumab in postmenopausal women with low bone mineral density . N. Engl. J. Med. 354 ( 8 ): 821 – 831 .
- Cummings , S.R. , San Martin , J. , McClung , M.R. et al. ( 2009 ). Denosumab for prevention of fractures in postmenopausal women with osteoporosis . N. Engl. J. Med. 361 ( 8 ): 756 – 765 .
- Jamal , S.A. , Ljunggren , O. , Stehman-Breen , C. et al. ( 2011 ). Effects of denosumab on fracture and bone mineral density by level of kidney function . J. Bone Miner. Res. 26 ( 8 ): 1829 – 1835 .
- Hernández , E. , Valera , R. , Alonzo , E. et al. ( 2003 ). Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis . Kidney Int. 63 ( 6 ): 2269 – 2274 .
- Haghverdi , F. , Farbodara , T. , Mortaji , S. et al. ( 2014 ). Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 . Iran. J. Kidney Dis. 8 ( 6 ): 461 – 466 .
- Ishani , A. , Blackwell , T. , Jamal , S.A. et al. ( 2008 ). The effect of raloxifene treatment in postmenopausal women with CKD . J. Am. Soc. Nephrol. 19 ( 7 ): 1430 – 1438 .
- Palmer , S. , Chung , E. , McGregor , D. et al. ( 2017 ). Interventions for preventing bone disease in kidney transplant recipients . Cochrane Database Syst. Rev . 10.1002/14651858.CD005015.pub4 Article number CD005015
- Tong , A. , Crowe , S. , Chando , S. et al. ( 2015 ). Research priorities in CKD: report of a National Workshop Conducted in Australia . Am. J. Kidney Dis. 66 ( 2 ): 212 – 222 .
- Heiwe , S. and Jacobson , S.H. ( 2011 ). Exercise training for adults with chronic kidney disease . Cochrane Database Syst. Rev. ( 10 ) (Art. No.:Cd003236).
